Gyre Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
| Przychód (średnia) |
101.39 |
125.50 |
238.00 |
356.25 |
596.30 |
| Przychód Δ r/r |
0.00% |
23.79% |
89.64% |
49.68% |
67.38% |
| Przychód (min) |
101.39 |
125.50 |
238.00 |
356.25 |
596.30 |
| Przychód (max) |
101.39 |
125.50 |
238.00 |
356.25 |
596.30 |
| EBITDA (średnia) |
-13.23 |
-16.37 |
-31.05 |
-46.48 |
-77.80 |
| EBIT (średnia) |
-13.73 |
-17.00 |
-32.23 |
-48.25 |
-80.76 |
| EBIT % |
-13.54% |
-13.54% |
-13.54% |
-13.54% |
-13.54% |
| Zysk netto (średni) |
17.39 |
12.28 |
119.68 |
175.94 |
295.63 |
| Zysk netto % |
17.15% |
9.78% |
50.29% |
49.39% |
49.58% |
| EPS (średnia) |
0.17 |
0.12 |
1.17 |
1.72 |
2.89 |
| Liczba analityków (Przychody) |
1 |
1 |
1 |
1 |
1 |
| Liczba analityków (EPS) |
1 |
1 |
1 |
1 |
1 |
| symbol |
GYRE |
GYRE |
GYRE |
GYRE |
GYRE |